FDA-CDER-CDRH, SNMMI, and MITA Workshop: Quantitative Brain Amyloid PET Imaging - 11/17/2022
This workshop is intended for a diverse group of scientists, responsible for the evaluation of quantitative positron emission tomography (PET) measures of amyloid deposition in the brain in clinical trials and clinical use in patients with suspected or confirmed Alzheimer's disease.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: FDA Source Type: news
More News: Alzheimer's | Brain | Clinical Trials | Drugs & Pharmacology | Neurology | PET Scan | Workshops